Clinical Trials on PD-1 Antibody in Belgium

Total 198 results

Janssen Sciences Ireland UC

Completed

A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects

Immunodeficiency Virus Type 1, Human

United States, France, Poland, United Kingdom, Belgium, Germany, Spain, Canada, Russian Federation, Puerto Rico
AstraZeneca
PRA Health Sciences

Completed

Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck

United States, Belgium, Canada, France, Spain, Korea, Republic of, Hungary, Malaysia, United Kingdom, Taiwan, Germany, Georgia, Israel, Czechia
Novo Nordisk A/S

Completed

Comparison of Efficacy and Safety of Insulin Detemir and NPH Insulin in Children and Adolescents With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany, France, Denmark, Sweden, Netherlands, Belgium, Finland, Macedonia, The Former Yugoslav Republic of, Norway, Israel, Spain, Croatia, Slovenia, United Kingdom, Switzerland, Ireland
UCB Biopharma SRL

Terminated

A Study to Test the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis

Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis

United States, Australia, Belgium, France, Germany, Italy, Netherlands, Spain, United Kingdom
NEAT ID Foundation
Gilead Sciences

Completed

HIV-1 & Coronavirus-Coinfection in Europe: Morbidity & Risk Factors of COVID-19 in People Living With HIV (HIV CoCo)

COVID-19 | HIV-1-infection

Spain, Germany, Netherlands, United Kingdom, France, Belgium, Italy, Greece
InflaRx GmbH

Completed

Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis. (IXchange)

Granulomatosis With Polyangiitis (GPA) | Microscopic Polyangiitis (MPA)

Germany, Russian Federation, Belgium, France, Spain, Czechia, Italy, Netherlands, Sweden, Switzerland, United Kingdom
AstraZeneca

Completed

Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer (EAGLE)

Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN

United States, France, Italy, Spain, Belgium, Czechia, Romania, Taiwan, Korea, Republic of, Brazil, Hungary, Japan, Russian Federation, Australia, Germany, Israel, Serbia, Bulgaria, Ukraine, Argentina, Poland, Chile, Croatia, Georgia
GlaxoSmithKline

Completed

Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921

Churg-Strauss Syndrome | Eosinophilic Granulomatosis With Polyangiitis

United States, France, Japan, Germany, Canada, United Kingdom, Belgium
Pfizer

Terminated

A Clinical Trial Comparing Efficacy and Safety of Exubera® and Humalog®

Diabetes Mellitus, Type 1

Denmark, Spain, Sweden, United States, Belgium, Austria, France, Portugal, Ireland, United Kingdom, Finland, Netherlands, Norway
Eli Lilly and Company
Boehringer Ingelheim

Completed

A Study in Adults With Type 1 Diabetes (ELEMENT 1)

Diabetes Mellitus, Type 1

Japan, United States, Greece, Belgium, Poland, Germany, Hungary, Mexico, Romania
Provention Bio, a Sanofi Company

Active, not recruiting

Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension)

Diabetes Mellitus, Type 1

United States, Belgium, Canada, Czechia, France, Germany, Poland, United Kingdom
Alnylam Pharmaceuticals

Active, not recruiting

A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 (ILLUMINATE-C)

Primary Hyperoxaluria Type 1 | Primary Hyperoxaluria

United States, Italy, France, Lebanon, Belgium, Netherlands, Israel, United Arab Emirates, Australia, Jordan, Turkey
Novartis Pharmaceuticals

Completed

Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients

Chronic Hepatitis C Genotype-1 Relapse

Belgium, United States, Germany, Spain, Puerto Rico, Taiwan, Australia
University of Pennsylvania
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaborators

Completed

Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis (PEXIVAS)

Microscopic Polyangiitis (MPA) | Granulomatosis With Polyangiitis (Wegener's) (GPA)

United States, Belgium, France, United Kingdom, Denmark, Canada, Japan, Australia, New Zealand, Sweden, Czechia, Italy, Greece, Mexico, Norway
Novo Nordisk A/S

Completed

Comparison of Biphasic Human Insulin 30 With Biphasic Insulin Aspart in Subjects With Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

United Kingdom, France, Netherlands, Belgium, Ireland
Novo Nordisk A/S

Completed

Evaluation of the Efficacy and Safety of Insulin Detemir Compared With That of NPH Insulin in Subjects With Type 1 Diabetes.

Diabetes Mellitus, Type 1

United Kingdom, Denmark, Sweden, Netherlands, Belgium, Finland, France, Australia, Ireland, Norway
Novo Nordisk A/S

Completed

Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes (BEGIN™)

Diabetes | Diabetes Mellitus, Type 1

United States, Poland, United Kingdom, Belgium, Norway, Germany, Greece
Eli Lilly and Company
Alkermes, Inc.

Completed

Evaluate the Efficacy of Insulin Patients With Type 1 Diabetes

Diabetes Mellitus, Type 1

United States, Belgium, India, Italy, Argentina, France, Germany, Mexico, Puerto Rico
Novo Nordisk A/S

Completed

Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 Diabetes (Onset® 5)

Diabetes | Diabetes Mellitus, Type 1

United States, Russian Federation, United Kingdom, Canada, France, Netherlands, Belgium, Germany, Slovenia
Novo Nordisk A/S

Completed

A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus

Diabetes | Diabetes Mellitus, Type 1

United States, India, Russian Federation, Belgium, Spain, Israel, Croatia, Serbia, North Macedonia, South Africa, Slovenia, Brazil, Poland, Canada, Czechia
GlaxoSmithKline

Recruiting

Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) (OCEAN)

Eosinophilic Granulomatosis With Polyangiitis

Canada, France, Italy, Spain, Belgium, Korea, Republic of, United States, Japan, China, Czechia, Hungary, Israel, Portugal, Poland, Netherlands, United Kingdom, Austria, Argentina, Australia, Brazil, Germany, Sweden
Novo Nordisk A/S

Completed

A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function

Diabetes | Diabetes Mellitus, Type 1

United States, Israel, Italy, Poland, Russian Federation, United Kingdom, Canada, Denmark, Sweden, Austria, Belgium, Spain, Ireland, Norway, Serbia, Finland, Portugal, Ukraine
Boehringer Ingelheim
Eli Lilly and Company

Completed

Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)

Diabetes Mellitus, Type 1

United States, Spain, Taiwan, Belgium, United Kingdom, Germany, Canada, Australia, Finland, Netherlands, Poland, France, Denmark, Norway, Sweden, Austria, Czechia
Novo Nordisk A/S

Completed

The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes (ADJUNCT TWO™)

Diabetes | Diabetes Mellitus, Type 1

United States, Italy, Canada, Denmark, Finland, Spain, Netherlands, Austria, Sweden, Belgium, France, Bulgaria, South Africa
Eli Lilly and Company

Completed

A Study in Participants With Type I Diabetes Mellitus (IMAGINE 3)

Diabetes Mellitus, Type 1

United Kingdom, United States, Australia, Canada, Poland, Denmark, Spain, Croatia, Sweden, Greece, Belgium, France, New Zealand, South Africa, Israel, Brazil, Ireland, Netherlands, Lithuania, Slovakia
Novo Nordisk A/S

Completed

The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes (ADJUNCT ONE™)

Diabetes | Diabetes Mellitus, Type 1

United States, Israel, Poland, United Kingdom, France, Sweden, Netherlands, Finland, Belgium, Ireland, Germany, Canada, Russian Federation, Australia, Norway, Argentina, Ukraine
Alnylam Pharmaceuticals

Recruiting

BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1) (BONAPH1DE)

Primary Hyperoxaluria Type 1

France, Spain, United States, Israel, Belgium, Switzerland, Germany, United Kingdom, Italy, Canada
Novo Nordisk A/S

Completed

Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes (onset® 1)

Diabetes | Diabetes Mellitus, Type 1

United States, Poland, Finland, Belgium, Hungary, United Kingdom, Germany, Canada, Czechia
Pfizer
Medivation, Inc.

Completed

A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) (EMBRACA)

Breast Neoplasms | BRCA 1 Gene Mutation | BRCA 2 Gene Mutation

Korea, Republic of, United States, Australia, Spain, Belgium, France, Ireland, Taiwan, Poland, Germany, Israel, Brazil, United Kingdom, Italy, Russian Federation, Ukraine
Eli Lilly and Company
Alkermes, Inc.

Completed

Study of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes

Diabetes Mellitus, Type 1

United States, Belgium, Canada, Croatia, Hungary, India
Incyte Corporation

Active, not recruiting

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors

Cervical Cancer | Nasopharyngeal Carcinoma | Mesothelioma | Advanced Solid Tumor | Small-cell Lung Cancer | Esophageal Squamous Cell Carcinoma | Urothelial Carcinoma | Merkel Cell Carcinoma | HepatoCellular Carcinoma | Cutaneous Squamous Cell Carcinoma | MSI-H/dMMR Tumors | PD-L1 Amplified Tumor (9p24.1)

France, United States, Japan, Belgium, Australia
Bristol-Myers Squibb

Completed

Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus

Hepatitis C, Genotype 1

United States, Australia, France, Germany, Spain, Canada, Puerto Rico, Argentina, Brazil, Russian Federation, United Kingdom, Italy, Belgium
Eli Lilly and Company

Completed

Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes

Diabetic Neuropathies | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Insulin-Dependent

United States, Spain, Hungary, Australia, Belgium, Denmark, Estonia, Germany, Israel
Pharnext S.C.A.
Premier Research Group plc; Eurofins Optimed; Synteract HCR (Syneos Health); Gr... and other collaborators

Active, not recruiting

Assessing Long Term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A (PLEO-CMT-FU)

Charcot-Marie-Tooth Disease, Type IA

United States, Belgium, Canada, France, Netherlands, Spain, United Kingdom
Tranzyme, Inc.

Completed

Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1 | Gastroparesis

United States, Belgium, Denmark, Finland, Germany, Norway, Poland, Sweden
Tibotec Pharmaceuticals, Ireland

Completed

TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors

HIV Infections | HIV-1

United States, France, United Kingdom, China, Belgium, Germany, Spain, Chile, Mexico, Portugal, Costa Rica, Panama, South Africa, Canada, Brazil, Puerto Rico, Russian Federation, Thailand, Australia, India
Pharnext SA

Completed

Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT) (PLEO-CMT)

Charcot-Marie-Tooth Disease Type 1A

United States, United Kingdom, Belgium, Canada, France, Netherlands, Spain, Germany
ViiV Healthcare
GlaxoSmithKline

Completed

HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive Adults

HIV-1 Infection | Infection, Human Immunodeficiency Virus I

Germany, Spain, France, Belgium, United Kingdom, Italy, Romania, Russian Federation, Switzerland
Incyte Corporation

Active, not recruiting

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

Cervical Cancer | Nasopharyngeal Carcinoma | Advanced Solid Tumors | Mesothelioma | Small-cell Lung Cancer | Esophageal Squamous Cell Carcinoma | Merkel Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Anal Carcinoma | Cutaneous Squamous Cell Carcinoma | MSI-H/dMMR Tumors | PD-L1 Amplified Tumor (9p24.1) | Urothelial... and other conditions

Finland, United States, United Kingdom, Belgium, Sweden, Denmark, Norway
Janssen R&D Ireland

Completed

Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants

Human Immunodeficiency Virus Type 1

United States, France, United Kingdom, Belgium, Spain, Switzerland, Sweden, Canada, Puerto Rico, Poland
Janssen Infectious Diseases BVBA
Vertex Pharmaceuticals Incorporated

Completed

VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection

Genotype 1 Chronic Hepatitis C | Treatment Naive

United States, Australia, France, Poland, United Kingdom, Belgium, Germany, Spain, Sweden, Brazil, Austria, Ireland, Mexico
University of Minnesota
National Institute of Allergy and Infectious Diseases (NIAID); National Institutes...

Recruiting

Respiratory Virus Hospitalization Study (FLU 003 Plus)

Influenza | Novel Respiratory Virus-1 Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV) | Novel Respiratory Virus-2 Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)

United States, Australia, Spain, Denmark, Greece, Argentina, United Kingdom, Belgium, Chile, Germany, Peru, Thailand
ViiV Healthcare

Terminated

A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults

HIV-1 Infection | Infection, Human Immunodeficiency Virus I

United States, France, Germany, Canada, Italy, Australia, Belgium, Portugal, Puerto Rico, Romania, United Kingdom
University of Oxford
American College of Rheumatology; The European League Against Rheumatism (EULAR) and other collaborators

Unknown

American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis (DCVAS)

Giant Cell Arteritis | Wegener's Granulomatosis | Microscopic Polyangiitis | Polyarteritis Nodosa | Takayasu Arteritis | Churg Strauss Syndrome

Korea, Republic of, United States, Germany, Australia, Japan, Ireland, Belgium, Italy, Denmark, Slovenia, Switzerland, Canada, Argentina, Austria, China, Czech Republic, Egypt, Finland, France, Hungary, India, Mexico, Netherlands, New... and more
AstraZeneca
Daiichi Sankyo Co., Ltd.

Recruiting

A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors (DPT02)

Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer | Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer

Canada, Korea, Republic of, Taiwan, United States, Italy, United Kingdom, Thailand, Russian Federation, India, Belgium, Australia, Poland, Spain, Japan, Brazil, Czechia, Netherlands
Novartis Pharmaceuticals

Recruiting

Pediatric Long-Term Follow-up and Rollover Study

Glioblastoma | Astrocytoma | Anaplastic Astrocytoma | Neurofibromatosis Type 1 | Anaplastic Ganglioglioma | Anaplastic Pleomorphic Xanthoastrocytoma | Ganglioglioma | Pleomorphic Xanthoastrocytoma | Diffuse Astrocytoma | Anaplastic Oligodendroglioma | Pilocytic Astrocytoma | Gangliocytoma | Central Neurocytoma | Oligodendroglioma... and other conditions

United States, Belgium, Spain, Denmark, Germany, Czechia, Italy, Australia, Russian Federation, France, Brazil, Netherlands, Japan, Canada, Finland, Sweden, United Kingdom, Argentina, Israel
AbbVie

Completed

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I)

Chronic Hepatitis C Virus (HCV) Infection Genotype 1

Algeria, Australia, Belgium, Bulgaria, Canada, Denmark, Finland, France, Germany, Greece, Israel, Italy, Mexico, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Saudi Arabia, Spain, Switzerland, Turkey, Austria, Ireland and more
European Organisation for Research and Treatment...
Pfizer

Completed

CREATE: Cross-tumoral Phase 2 With Crizotinib (CREATE)

Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma | Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor | Locally Advanced and/or Metastatic Papillary Renal Cell Carcinoma Type 1 | Locally Advanced and/or Metastatic Alveolar Soft Part Sarcoma | Locally Advanced... and other conditions

France, Belgium, Netherlands, Germany, United Kingdom, Italy, Norway, Poland, Slovakia, Slovenia

Clinical Trials on PD-1 Antibody in Belgium

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gabon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations